IL1-beta: a new target for myeloma therapy
AssigneeMayo Foundation for Medical Education and Research
InventorsKathleen A. Donovan, John A. Lust
Life of this patent
Estimating the term…
Abstract
Diagnostic methods for the detection of multiple myeloma (MM) and the identification of high-risk patients with multiple myeloma-related plasma proliferative disorders, such as MGUS or SMM, likely to progress to active MM are described. The diagnosis is based on the determination of concentrations of bioactive IL-1β produced by the bone marrow plasma cells of these patients. Also described are therapeutic methods for the treatment of MM and for the chemoprevention of the progression from disorders such as MGUS and SMM to active MM, involving the administration of inhibitors of IL-1β.
Claims27
A method of quantitating IL-1β in a bone marrow preparation comprising;
- a) culturing stromal cells with said bone marrow prep aration;
- b) determining the amount of IL-6 produced by said stromal cell culture;
- and
- c) correlating the amount of IL-6 produced to the IL-1β concentration in said bone marrow preparation by comparison to a standard curve prepared by measuring IL-6 produced by stromal cells contacted with known concentrations of IL-1β.
A method of detecting multiple myeloma (MM) in an individual comprising:
- a) culturing stromal cells with a bone marrow preparation from said individual;
- and
- b) determining the amount of IL-6 produced by said stromal cell culture, wherein an elevated level of IL-6 is indicative of MM.
A method of identifying a patient with a multiple myeloma-related plasmaproliferative disorder likely to progress to active multiple myeloma (MM) comprising:
- a) culturing stromal cells with a bone marrow preparation from said patient;
- and
- b) determining the amount of IL-6 produced by said stromal cell culture, wherein an elevated level of IL-6 is indicative of a likelihood said patient will progress to active MM.
A method of identifying a patient with a multiple myeloma-related plasmaproliferative disorder likely to progress to active multiple myeloma (MM) comprising:
- a) culturing a bone marrow preparation from said patient with a T-cell line that produces IL-2 in response to IL-1β;
- b) determining the amount of IL-2 produced by said T-cell line;
- and
- c) identifying said patient as likely to progress to MM if said amount of IL-2 is elevated.
A method of monitoring the effectiveness of the treatment of a patient multiple myelom (MM) comprising:
- a) culturing stromal cells with a bone marrow preparation from said patient after the initiation of treatment;
- b) determining the amount of IL-6 produced by said stromal cell culture;
- and
- c) comparing said amount of IL-6 with a known standard or a patient determined standard.
A method of treating a patient with multiple myeloma (MM) comprising:
- a) identifying a patient with MM;
- and
- b) administering an inhibitor of interleukin-1J (IL-1J) to said patient.
A method of inhibiting interleukin-6 (IL-6) production by bone marrow stromal cells in a patient suffering from multiple myeloma (MM) or a multiple myeloma-related plamaproliferative disorder comprising administering an inhibitor of interleukin-1β (IL-1β to said patient in an amount effective to inhibit the production of IL-6 by said bone marrow stromal cells.
A method of inhibiting interleukin-6 induced myeloma cell proliferation in a patient suffering from multiple myeloma (MM) or a multiple myeloma-related plamaproliferative disorder comprising administering an inhibitor of interleukin-1β (IL-1β) to said patient in an amount sufficient to inhibit myeloma cell proliferation.
A method of inhibiting the progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) in a patient suffering from MGUS comprising administering an inhibitor of interleukin-1β (IL-1β) to said patient.
A method of inhibiting the progression from smoldering multiple myeloma (SMM) to multiple myeloma (MM) in a patient suffering from SMM comprising administering an inhibitor of interleukin-1β (IL-1β) to said patient.
A kit comprising:
- a) an inhibitor of bioactive IL-1β;
- b) a negative control for the inhibitor of bioactive IL-1β;
- and
- c) a positive control for bioactive IL-1β.
Dependencies are inferred from the claim text.